TNFRSF17 and Miyoshi myopathy: RV prepared anti-BCMA CAR-T cells combined with ASCT for the treatment of MM patient in clinical practice was reported, indicating that the RV-based anti-BCMA-CAR-T cells with ASCT treatment had excellent therapeutic efficacy, high safety and cost-control advantages in triple-refractory MM patients.